1. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy

2. Overview of irAEs

3. Immune-Related Pneumonitis

4. Case Presentation: A 65-Year-Old Woman With Cough and Shortness of Breath

5. General Management Principles

6. General Management Principles (cont)

7. Pneumonitis

8. Grading Pneumonitis

9. Incidence of Pneumonitis

10. Timing of Onset Varies

11. Radiologic Features Vary

12. Case (cont)

13. Variable Pathologic Features

14. Early Management Algorithm

15. Immune-Related Toxicity Guidelines

16. Case (cont)

17. Ongoing Challenges With Anti-PD-1/PD-L1-Related Pneumonitis

18. Optimizing Immunosuppression for Anti-PD-1/PD-L1 Pneumonitis

19. Immune-Related Hepatitis

20. Case Presentation: A 55-Year-Old Woman With Elevated LFTs

21. Overview of Immune-Related Hepatitis

22. Screening for Immune-Related Hepatitis

23. Diagnosing Immune-Related Hepatitis

24. Grading Hepatitis Severity

25. Management of Grades 1 and 2 Hepatitis

26. Management of Grades 3 and 4 Hepatitis

27. Return to the Case

28. Steroid-Refractory Hepatitis

29. Case Conclusion

30. Immune-Related Colitis

31. Case Presentation: A 54-Year-Old Man With Diarrhea

32. How to Proceed?

33. Grading Diarrhea/Colitis

34. Working With Uncertainties

35. Return to the Case

36. Managing Diarrhea/Colitis

37. Notes on Tapering Steroids

38. Return to the Case

39. Return to the Case (cont)

40. Infliximab

41. Considering Endoscopy

42. Moving Forward

43. Overview of GI Toxicity

44. When Do GI irAEs Occur?

45. Abbreviations

46. Abbreviations (cont)